



Hollis-Eden Pharmaceuticals, Inc.

4435 Eastgate Mall, Suite 400

San Diego, CA 92121

Telephone: 858 587 9333

Fax: 858 558 6470



Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY "FIRST-CLASS MAIL"

Attorney Docket No. : 202.3

Serial No. : 09/820,483

Applicant(s) : Clarence N. Ahlem, et al.

For : Immune Modulation Method Using Steroid Compounds

Attorney : Daryl D. Muenchau, Registration No. 36,616


I hereby certify that the accompanying

Information Disclosure Statement Transmittal in duplicate; Information Disclosure Statement (substitute for Form 1449) citing 77 references, copies of 35 of the cited references; and a Return Prepaid Postcard

are being deposited with the United States Postal Service "First-Class Mail" service on the date indicated below and are addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Nov 22, 2004
Date of Deposit

Candace Fuller
Candace Fuller



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.
Application No. : 09/820,483
Filed : November 22, 2004
Title : IMMUNE MODULATION METHOD USING STEROID
COMPOUNDS

Examiner : E. Peselev
TC/A.U. : 1623

Docket No. : 202.3
Customer No. : 26551

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT TRANSMITTAL

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is a substitute form for form PTO-1449 listing 77 references, copies of 35 of the cited references, a certificate of mailing under 37 C.F.R. § 1.8 and postage prepaid return postcard. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c). Please charge the \$180.00 fee or credit any overpayments to **Deposit Account No. 501536**. A duplicate copy of this transmittal sheet is enclosed.

Please direct all correspondence to **Customer No. 26,551**.

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: Nov 22, 2004

By: Daryl D. Muenchau

Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: 858-587-9333

Customer No. 26,551

12/01/2004 WABDELRI 00000102 501536 09820483

01 FC:1806 180.00 DA

Substitute for form 1449/PTO U.S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY) DISCLOSURE STATEMENT SUBMISSION DATE: November 22, 2004	Application Number	09/820,483
	Filing Date	March 29, 2001
	First Named Inventor	Clarence N. Ahlem
	Art Unit	1623
	Examiner Name	E. Peselev
	Attorney Docket Number	202.3

U.S. PATENT DOCUMENTS			
EXAMINER INITIAL	DOCUMENT NUMBER - KIND CODE	ISSUE DATE OR PUBLICATION DATE	PATENTEE OR APPLICANT NAME
	U.S. 5,700,793	12-23-1997	Schwartz et al.
	U.S. 5,001,119	03-19-1991	Schwartz et al.
	U.S. 4,602,003	07-22-1986	Malinow
	U.S. 4,242,502	12-30-1980	Malinow et al.
	U.S. 4,602,003	07-22-1986	Malinow
	U.S. 5,502,038	03-26-1996	Malinow
	U.S. 5,629,295	05-13-1997	Deninno et al.
	U.S. 6,465,445 B1	10-15-2002	Labrie
	U.S. 2003/0083231 A1	05-01-2003	Ahlem et al.
	U.S. 20040019026 A1	01-29-2004	Schwartz
	U.S. 2004/0097406 A1	05-20-2004	Ahlem et al.
	U.S. 2004/0116359 A1	06-17-2004	Ahlem et al.
	U.S. 2003/0060425 A1	03-27-2003	Ahlem et al.
	U.S. 20040220161 A1	11-04-2004	Ahlem et al.
	U.S. 20040034003 A1	02-19-2004	Schwartz et al.
	U.S. 2004/0043973 A1	03-04-2004	Ahlem et al.
	U.S. 2004/0138187 A1	07-15-2004	Ahlem et al.
	U.S. 20040220114 A1	11-04-2004	Ahlem et al.
	U.S. 5,837,269	11-17-1998	Araneo et al.
	U.S. 5,656,621	08-12-1997	Schwartz et al.
	U.S. 5,744,462	04-28-1998	Schwartz et al.
	U.S. 5,919,465	07-06-1999	Daynes et al.
	U.S. 5,532,230	07-02-1996	Daynes et al.
	U.S. 5,807,848	09-15-1998	Lardy
	U.S. 3,045,032	07-17-1962	Robinson et al.
	U.S. 5,696,106	12-09-1997	Schwartz et al.
	U.S. 3,045,030	07-17-1962	Robinson et al.

EXAMINER SIGNATURE	DATE CONSIDERED	
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.		

Substitute for form 1449/PTO U.S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY) Disclosure Statement Submission Date: November 22, 2004	Application Number	09/820,483
	Filing Date	March 29, 2001
	First Named Inventor	Clarence N. Ahlem
	Art Unit	1623
	Examiner Name	E. Peselev
	Attorney Docket Number	202.3

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER - KIND CODE	ISSUE DATE OR PUBLICATION DATE	PATENTEE OR APPLICANT NAME
	U.S. 5,709,878	01-20-1998	Rosenbaum et al.
	U.S. 6,090,800	07-18-2000	Unger et al.
	U.S. 6,093,707	07-25-2000	Cook et al.
	U.S. 2002/0193357	12-19-2002	Song et al.
	U.S. 2003/0153541	08-14-2003	Dudley et al.
	U.S. 6,146,658	11-14-2000	Bosslet et al.
	U.S. 5,714,481	02-03-98	Schwartz et al.
	U.S. 5,753,640	05-19-98	Araneo, et al.
	U.S. 5,912,240	06-15-99	Loria
	U.S. 5,929,060	07-27-99	Araneo
	U.S. 6,110,906	08-29-00	Labrie, et al.
	U.S. 6,117,446	09-12-00	Place
	U.S. 3,872,076	03-18-1975	Rosen

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER - KIND CODE	PUBLICATION DATE	PATENTEE OR APPLICANT NAME	T ¹
	WO 99/39715 A1	8-12-1999	Stohler	
	WO 99/18977 A1	4-22-1999	Stohler	
	WO 95/10527 A1	4-20-1995	Christensen et al.	
	EP 0 289 327 A1	11-02-1988	Holt et al.	
	EP 0 133 995 B1	03-13-1985	Schwartz et al.	

1 - English language translation attached.

EXAMINER INITIAL	NON-PATENT LITERATURE DOCUMENTS AUTHOR, TITLE, DATE, PAGES, ETC.	T ¹
	FAREIN, I. et al., Transformation <i>in vitro</i> of [4- ¹⁴ C]-dehydroepiandrosterone into 7-oxygenated derivatives by normal human male and female skin tissue, <i>J. Investigative Dermatology</i> 52:357-361 1969	

EXAMINER SIGNATURE	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Substitute for form 1449/PTO U.S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY) SHEET 3 OF 4 Disclosure Statement Submission Date: November 22, 2004	Application Number	09/820,483
	Filing Date	March 29, 2001
	First Named Inventor	Clarence N. Ahlem
	Art Unit	1623
	Examiner Name	E. Peselev
	Attorney Docket Number	202.3

EXAMINER INITIAL	NON-PATENT LITERATURE DOCUMENTS AUTHOR, TITLE, DATE, PAGES, ETC.	T ¹
	SMART, E.J. et al., Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport, <i>Proc. Natl. Acad. Sci. USA</i> 101:3450-3455 2004	
	KOTHAPALLI, D. et al., Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation, <i>J. Clin. Invest.</i> 113:609-618 2004	
	BALLANTYNE, C.M. et al., Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia, <i>Int. J. Clin. Pract.</i> 58:653-658 2004	
	DUNCAN, B.B. et al., Fibrinogen, other putative markers of inflammation, and the weight gain in middle-aged adults - the ARIC study, <i>Obesity Research</i> 8:279-286 2000	
	NEIMANN-JÖNSSON, A. et al., Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor- α expression, <i>Arteriosclerosis Thromb. Vasc. Biol.</i> 20:2205-2211 2000	
	BEERS, M.H. et al. eds., <i>The Merck Manual of Diagnosis and Therapy</i> , 17 th ed., chapter 201, pages 1654-1658 1999	
	KANG, I. et al., Dehydroepiandrosterone and β -endorphin enhance interleukin-12 gene expression, <i>Chem. Abstracts</i> , vol. 126, No. 9 abstract No. 113406 1997	
	KNOPP, R.H. et al, Evaluation of the efficacy, safety and tolerability of ezetimibe in primary hypercholesterolaemia: A pooled analysis from two controlled Phase III clinical studies, <i>Int. J. Clin. Pract.</i> 57(5):363-368 2003	
	SCHWARTZ, A. et al., Dehydroepiandrosterone: an anti-obesity and anti-carcinogenic agent, <i>Nutr. Cancer</i> 3(1):46-53 1981	
	BEN-NATHAN, D. et al., Protection by dehydroepiandrosterone in mice infected with viral encephalitis, <i>Arch. Virol.</i> 120:263-271 1991	
	WOODS, M.L. et al., Treatment of aged mice with dehydroepiandrosterone provides an adjuvant effect in the immunization with recombinant hepatitis B surface antigen, <i>J. Immunology</i> 150(8 part 2):77a 1993	
	RASMUSSEN, K.R. et al., Effects of dehydroepiandrosterone in immunosuppressed adult mice infected with <i>Cryptosporidium parvum</i> , <i>J. Parasitology</i> 81(3):429-433 1995	
	PASHKO, L. et al., Dehydroepiandrosterone (DHEA) and 3 beta-methylandro-5-en-17-one: inhibitors of 7,12-dimethylbenz[a]anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin papilloma formation in mice, <i>Carcinogenesis</i> 5(4):463-466 1984	
	MCGILL, H.C. et al., Obesity accelerates the progression of coronary atherosclerosis in young men, <i>Circulation</i> 105:2712-2718 2002	
	ARAGHI-NIKNAM, M. et al., Cytokine dysregulation and Increased oxidation is prevented by dehydroepiandrosterone in mice infected with murine leukemia retrovirus, <i>Proc. Soc. Exp. Biol. Med.</i> 216(3):386-391 1997	
	YANG, J. et al., Inhibition of HIV-1 Latency Reactivation by Dehydroepiandrosterone (DHEA) and an Analog of DHEA, <i>Aids Research and Human Retroviruses</i> 9(8):747-754 1993	
	HENDERSON, E. et al., Dehydroepiandrosterone and 16 α -bromo-epiandrosterone: inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes, <i>Carcinogenesis</i> , 2(7):683-686 1981	
	ZHANG, Z. et al., Prevention of immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection, <i>Immunology</i> 96:291-297 1999	
	ARAGHI-NIKNAM, M. et al., Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS), <i>Immunology</i> 90:344-349 1997	
	BEBO, B.F. et al., Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells, <i>J. Immunol.</i> 162(1):35-40 1999	
	XIA, P. et al., Anti-AIDS agents. Part 36: 17-Carboxylated steroids as potential anti-HIV agents, <i>Bioorg. Med. Chem.</i> 7(9):1907-1911 1999	

EXAMINER SIGNATURE	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Substitute for form 1449/PTO U.S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY) SHEET 4 OF 4 Disclosure Statement Submission Date: November 22, 2004	Application Number	09/820,483
	Filing Date	March 29, 2001
	First Named Inventor	Clarence N. Ahlem
	Art Unit	1623
	Examiner Name	E. Peselev
	Attorney Docket Number	202.3

EXAMINER INITIAL	NON-PATENT LITERATURE DOCUMENTS AUTHOR, TITLE, DATE, PAGES, ETC.	T ¹
	MANZ, B. et al., Methyl 17 β -carboxyester derivatives of natural and synthetic glucocorticoids: Correlation between receptor binding and Inhibition of <i>in vitro</i> phytohaemagglutinin-induced lymphocyte blastogenesis, <i>J. Clin. Chem. Clin. Biochem.</i> 21(2):69-75 1983	
	KANG, I. et al, Dehydroepiandrosterone and β -endorphin enhance interleukin-12 gene expression, <i>J. Korean Soc. Microbiol.</i> 31(4):399-404 1996	✓
	INSERRA, P. et al., Modulation of Cytokine Production by Dehydroepiandrosterone (DHEA) Plus Melatonin (MLT) Supplementation of Old Mice, <i>Proc. Soc. Exp. Biol. Med.</i> 218(1):76-82 1998	
	SIGG, H.P. et al., 3 α -Acetoxyätiën-(8:9 oder 8:14)-säure-methylester, <i>Helvetica Chimica Acta</i> 39(6):1507-1525 1956	✓
	HERNANDEZ-PANDO, R. et al., The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice, <i>Immunology</i> 95(2):234-241 1998	
	LORIA, R., et al., "Control of the Immune Response by DHEA and its Metabolites", <i>Jpn. J. Clin Pathol</i> , vol. 46: pp. 505-517 (1998)	
	PASHKO, L., et al., "Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids", <i>Carcinogenesis</i> , vol. 2, p. 717-721 (1981)	
	SHEARER, G., "HIV-Induced Immunopathogenesis", <i>Immunity</i> , vol. 9, p. 587-593 (1998)	

1 - English language translation attached.

EXAMINER SIGNATURE	DATE CONSIDERED	
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.		